stoxline Quote Chart Rank Option Currency Glossary
Cabaletta Bio, Inc. (CABA)
9.93  -0.12 (-1.19%)    05-30 16:00
Open: 10.09
High: 10.26
Volume: 715,590
Pre. Close: 10.05
Low: 9.72
Market Cap: 479(M)
Technical analysis
2024-05-30 4:40:22 PM
Short term     
Mid term     
Targets 6-month :  13.93 1-year :  15.52
Resists First :  11.92 Second :  13.29
Pivot price 11.55
Supports First :  9.72 Second :  8.08
MAs MA(5) :  10.55 MA(20) :  11.79
MA(100) :  18 MA(250) :  16.23
MACD MACD :  -1 Signal :  -1
%K %D K(14,3) :  3.9 D(3) :  5.1
RSI RSI(14): 30.3
52-week High :  26.35 Low :  9.55
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CABA ] has closed above bottom band by 5.0%. Bollinger Bands are 25.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 10.33 - 10.43 10.43 - 10.49
Low: 9.51 - 9.64 9.64 - 9.72
Close: 9.78 - 9.99 9.99 - 10.12
Company Description

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Headline News

Thu, 30 May 2024
Cabaletta Bio to Share Insights at Jefferies Global Healthcare Conference - MyChesCo

Wed, 29 May 2024
Swiss National Bank Reduces Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Mon, 27 May 2024
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update -

Sun, 26 May 2024
HC Wainwright Reiterates Buy Rating for Cabaletta Bio (NASDAQ:CABA) - Defense World

Wed, 22 May 2024
We Think Cabaletta Bio (NASDAQ:CABA) Can Afford To Drive Business Growth - Yahoo Finance

Wed, 22 May 2024
Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 48 (M)
Shares Float 39 (M)
Held by Insiders 3.2 (%)
Held by Institutions 109.8 (%)
Shares Short 10,250 (K)
Shares Short P.Month 8,500 (K)
Stock Financials
EPS -1.65
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.94
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -25.2 %
Return on Equity (ttm) -39.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.52
Qtrly Earnings Growth 0 %
Operating Cash Flow -54 (M)
Levered Free Cash Flow -30 (M)
Stock Valuations
PE Ratio -6.02
PEG Ratio 0
Price to Book value 2.01
Price to Sales 0
Price to Cash Flow -8.95
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android